tert-butyl cyclooctyl ether | 95363-61-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl cyclooctyl ether
• 英文别名: tert-butoxycyclooctane；cyOtBu；(2-Methylpropan-2-yl)oxycyclooctane
• CAS: 95363-61-4
• 化学式: C₁₂H₂₄O
• 分子量: 184.322
• InChiKey: MLKJUUVULVXAMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  过氧化苯甲酸叔丁酯 、 cyclooctyl magnesium bromide 生成 tert-butyl cyclooctyl ether
  参考文献：
  名称：

  Herwig,K. et al., Chemische Berichte, 1975, vol. 108, p. 1421 - 1436

  摘要：

  DOI：

文献信息

• Oxidorhenium(V) Complexes with Phenolate‐ and Carboxylate‐Based Ligands: Structure and Catalytic Epoxidation
  作者：Barbara Machura、Mariusz Wolff、Dominik Tabak、Jörg A. Schachner、Nadia C. Mösch‐Zanetti

  DOI：10.1002/ejic.201200277

  日期：2012.8

  Several oxidorhenium(V) complexes with phenolate- and carboxylate-based ligands were synthesized: [ReOCl(hpbi)2]·THF, [ReOCl(hmpbta)2], [ReOBr(hmpbta)2], [ReOCl(hpbo)2], [ReOCl(hpbt)2]·2MeCN, [ReO(OMe)(quin)2], [ReO(OMe)(pic)2], [ReO(OMe)(2,5-dipic)2]·C5H5N, [ReOCl(pic)2], and [ReOCl(3-ind)2] [in which Hhpbi = 2-(2-hydroxyphenyl)-1H-benzimidazole, Hhmpbta = 2-(2-hydroxy-5-methylphenyl)benzotriazole

  合成了几种具有酚盐和羧酸盐基配体的氧化铼(V)配合物：[ReOCl(hpbi)2]·THF、[ReOCl(hmpbta)2]、[ReOBr(hmpbta)2]、[ReOCl(hpbo)2] , [ReOCl(hpbt)2]·2MeCN, [ReO(OMe)(quin)2], [ReO(OMe)(pic)2], [ReO(OMe)(2,5-dipic)2]·C5H5N, [ReOCl(pic)2]和[ReOCl(3-ind)2] [其中Hhpbi = 2-(2-羟基苯基)-1H-苯并咪唑，Hhmpbta = 2-(2-羟基-5-甲基苯基)苯并三唑， Hhpbo = 2-(2-羟基苯基)-2-苯并恶唑，Hhpbt = 2-(2-羟基苯基)苯并噻唑，Hquin = 喹哪二酸，picH = 吡啶甲酸，2,5-dipicH = 2,5-吡啶二甲酸，和 3 -indH = 吲唑-3-羧酸]。通过光谱方
• Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K)
  申请人：Connolly Michael Kevin

  公开号：US20090227587A1

  公开（公告）日：2009-09-10

  The present invention provides pyrimidines of Formula I: wherein R 4 , R 6 , and Y have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

  本发明提供了式I的嘧啶类化合物：其中R4、R6和Y的值在说明书中有所定义，以及其药学上可接受的盐，可用作治疗疾病和病症的药物，包括炎症性疾病、心血管疾病和癌症。还提供了包含一种或多种式I化合物的药物组合物。
• BIOMOLECULE CONJUGATES
  申请人：Celgene Corporation

  公开号：EP3903826A1

  公开（公告）日：2021-11-03

  The present invention relates to biomolecule conjugates which comprise a biomolecule wherein at least one non-natural amino acid (NNAA) is integral to the structure of the biomolecule and wherein the NNAA is a point of attachment of a linker to which a payload, particularly a cytotoxic agent, is attached. More specifically, this invention relates to conjugates of cell-binding agents and active release products comprising cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction. Methods of production, pharmaceutical compositions and methods of use are provided.

  本发明涉及生物大分子共轭物，它包括生物大分子，其中至少有一个非天然氨基酸（NNAA）与生物大分子的结构不可分割，并且该非天然氨基酸是连接有效载荷（尤其是细胞毒剂）的连接点。更具体地说，本发明涉及细胞结合剂的共轭物和包含细胞毒剂的活性释放产物，其中共轭物是通过环化反应生产的。本发明还提供了生产方法、药物组合物和使用方法。
• Solvomercuration-demercuration. 12. The solvomercuration-demercuration of olefins in alcohol solvents with mercuric trifluoroacetate - an ether synthesis of wide generality
  作者：Herbert C. Brown、Joseph T. Kurek、Min Hon Rei、Kerry L. Thompson

  DOI：10.1021/jo00208a005

  日期：1985.4
• BROWN, H. C.;KUREK, J. T.;REI, MIN-HON;THOMPSON, K. L., J. ORG. CHEM., 1985, 50, N 8, 1171-1174
  作者：BROWN, H. C.、KUREK, J. T.、REI, MIN-HON、THOMPSON, K. L.

  DOI：——

  日期：——